Title: Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.
Journal: Cancer letters 20121201
Title: Predicting new indications for approved drugs using a proteochemometric method.
Journal: Journal of medicinal chemistry 20120809
Title: Characteristics and molecular basis of celecoxib modulation on K(v)7 potassium channels.
Journal: British journal of pharmacology 20111101
Title: Celecoxib and 2,5-dimethyl-celecoxib prevent cardiac remodeling inhibiting Akt-mediated signal transduction in an inherited dilated cardiomyopathy mouse model.
Journal: The Journal of pharmacology and experimental therapeutics 20110701
Title: Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib.
Journal: Cancer letters 20110501
Title: Dimethylcelecoxib inhibits mPGES-1 promoter activity by influencing EGR1 and NF-κB.
Journal: Biochemical pharmacology 20101101
Title: Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature.
Journal: Molecular cancer therapeutics 20100301
Title: Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.
Journal: Cancer letters 20090908
Title: Dimethylcelecoxib inhibits prostaglandin E2 production.
Journal: Biochemical pharmacology 20080701
Title: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Journal: Expert opinion on investigational drugs 20080201
Title: Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib.
Journal: Cancer research 20080201
Title: COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.
Journal: Molecular cancer 20080101
Title: CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Journal: Molecular pharmacology 20071101
Title: Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.
Journal: Molecular cancer therapeutics 20070401
Title: Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy.
Journal: Neurosurgical focus 20060415
Title: Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.
Journal: Molecular cancer 20060101
Title: Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib.
Journal: Blood 20051215
Title: Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.
Journal: Cancer biology & therapy 20050501
Title: DMC: novel celecoxib derivatives to rap cancer.
Journal: Cancer biology & therapy 20050501
Title: Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms.
Journal: Molecular cancer therapeutics 20041201
